Recently, a review described the current report of Ph+ AML clinical features and treatments compared to chronic myeloid leukemia primary in blast crisis (CML-BC).[9] It appeared that Ph+ AML presented basophils <2% in white blood cell (WBC), p190 positive and <100% BCR/ABL1 metaphases and there was no standardized treatment. This evidence concerns the gene ABL1 and breast cancer.